Dr. Bettina Hamelin
President and CEO, Innovative Medicines Canada (IMC)
"I'm a researcher at heart. I'm incredibly passionate about research and innovation, because research and innovation are critical pillars of a progressive society that cares about its people and about an equitable world for all."
Dr. Bettina Hamelin, PharmD, EMBA, is a globally renowned researcher and esteemed life sciences executive, who brings over 30 years of experience in academia, industry, and not-for-profit organizations to her current role as President of Innovative Medicines Canada (IMC).
In this role, Dr. Hamelin is dedicated to enhancing access to innovative medicines for Canadians, while advancing Canada’s position as an attractive destination for life sciences investments, high-value jobs, and new clinical trials. Driven by her unwavering commitment to improving the health and well-being of all Canadians, Dr. Hamelin firmly believes collaboration and partnership are essential to the future of healthcare innovation in Canada. Having acquired an Executive MBA in Healthcare from the Sauder School of Business at the University of British Columbia, she is uniquely positioned to work alongside health system stakeholders to find novel solutions to complex challenges.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Nulla malesuada pellentesque elit eget gravida. Egestas diam in arcu cursus.
Dr. Bettina Hamelin
Prior to joining IMC, Dr. Hamelin was the President and CEO of Ontario Genomics for over six transformative years. Here, she not only established the organization as Canada’s preeminent force in engineering biology on the world stage, but also cultivated an ecosystem that was conducive to the development and commercialization of cutting-edge Canadian innovations.
Dr. Hamelin’s illustrious career includes serving as the Vice-President of Research Partnerships at the Natural Sciences and Engineering Research Council of Canada (NSERC), where she led a 130-member team to spearhead a robust research and innovation investment strategy. She also held pivotal leadership roles at BioChem Pharma and Pfizer Inc., pioneering novel public-private partnership models that propelled research and innovation forward, and was a tenured professor at Université Laval.
Dr. Hamelin is fluently trilingual and holds a Doctor of Pharmacy degree from the University of Kentucky, US.
With her wealth of expertise, purpose-driven leadership, and passion for driving positive change in the pharmaceutical, health, and life sciences sectors, Dr. Hamelin stands as a trusted leader, poised to make enduring contributions to the health of Canadians and the vibrancy of Canada’s research and innovation ecosystems
Latest Resources
Prix Galien Canada – Product Innovation Award Submission Form
The Prix Galien Canada – Innovative Product Award will be presented to a drug, launched at least 12 months ago and no more than 60 months (5 years) ago, that has made the most significant overall contribution to patient care in Canada, according to the Jury of Prix Galien Canada.
Value of Medicines in Canada
This study examines and quantifies the value of innovative treatments in Canada to patient lives, the healthcare system and to society. Case studies include: HPV vaccines, Melanoma treatments, treatment for Rheumatoid Arthritis and Hepatitis C.
Developing a Canadian managed entry approach for new innovation: What can Canada learn from Europe?
Many new therapies coming to the market are not well served by the traditional drug reimbursement approaches currently employed by Canada’s public plans. A growing number of European regulatory authorities have been using novel managed entry agreements (MEA) and innovative access agreements (IAA) to accelerate approval times and improve availability to patients.
